Luveltamab Tazevibulin Elicits Response in Platinum-Resistant Ovarian Cancer, Low/Medium FRα Expression

Fact checked by Ashley Chan
News
Article

The REFRαME-O1 trial improved response in patients with FRα–positive platinum-resistant ovarian cancer, including those with low to medium expression when given luveltamab tazevibulin.

The REFRαME-O1 trial improved response in patients with FRα–positive platinum-resistant ovarian cancer, including those with low to medium expression when given luveltamab tazevibulin.

The REFRαME-O1 trial improved response in patients with FRα–positive platinum-resistant ovarian cancer, including those with low to medium expression when given luveltamab tazevibulin.

Good responses and a manageable safety profile were noted with luveltamab tazevibulin for patients with folate receptor alpha (FRα)–positive platinum-resistant ovarian cancer, including those with low to medium expression, according to results from the phase 2/3 REFRαME-O1 trial (NCT05870748) presented at the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer (SGO).

Data from the phase 2 portion showed that patients treated with luveltamab tazevibulin at 5.2 mg/kg plus prophylactic granulocyte–colony stimulating factor (G-CSF) for the first 2 cycles, then 4.3 mg/kg (n = 25) experienced an overall response rate (ORR) of 32% (95% CI, 17%-50%) and a disease control rate (DCR) of 96% (95% CI, 80%-99.9%). Best responses included complete response (4.0%), partial response (PR; 28.0%), stable disease (SD; 68.0%), and progressive disease (PD; 4.0%). The median time to response was 6.0 weeks (range, 4.7-11).

Notably, in this cohort, patients with low-to-median FRα expression (n = 12), defined as an FRα level of at least 25% and less than 75%, the ORR was 33.3% (95% CI, 12.3%-60.9%) with a DCR of 91.7% (95% CI, 61.5%-99.8%). In those with high FRα expression of at least 75% (n = 13), the ORR and DCR were 30.8% (95% CI, 9.1%-61.4%) and 100% (95% CI, 75.3%-100%), respectively.

Those treated at dose of 4.3 mg/kg in cycle 1 and beyond (n = 29) achieved an ORR of 13.8% (95% CI, 3.9%-32%) and a DCR of 69% (95% CI, 49%-85%). Best responses comprised PR (13.8%), SD (55.2%), and PD (31.0%). The median time to response was 6.4 weeks (range, 5.4-11.9).

“[Luveltamab tazevibulin] demonstrated clinical activity with an ORR over 30% in patients with platinum-resistant ovarian cancer and an FRα expression greater than 25% by tumor proportion score, which comprises 80% of all high-grade serous carcinoma,” lead study author Jung-Yun Lee, MD, PhD, associate professor in the Department of Obstetrics and Gynecology at Yonsei University College of Medicine in Seoul, South Korea, said in a presentation of the data.

Trial Design

REFRαME-O1 is a phase 2/3 trial that is currently enrolling patients for the phase 3 portion, where patients are being randomly assigned 1:1 to receive luveltamab tazevibulin or investigator’s choice of chemotherapy.

In the phase 2 portion of the study, investigators enrolled patients with platinum-resistant ovarian cancer who had an FRα expression of at least 25% at any staining intensity. One to 3 prior lines of therapy were required, as was an ECOG performance status of 0 or 1. Patients with primary platinum-refractory disease were excluded.

Patients enrolled in phase 2 were randomly assigned 1:1 to receive luveltamab tazevibulin given once every 3 weeks at a starting dose of 5.2 mg/kg with prophylactic G-CSF for the first 2 cycles, then at 4.3 mg/kg in subsequent cycles; or luveltamab tazevibulin at 4.3 mg/kg once every 3 weeks starting in cycle 1.

The primary end points of phase 2 were safety, investigator-assessed ORR per RECIST 1.1 criteria, and pharmacokinetics.

Lee noted that the baseline characteristics were well balanced between the phase 2 arms. The median age was 60.5 years (range, 41-81) in the 5.2-mg/kg cohort (n = 28) and 59.0 years (range, 42-81) in the 4.3-mg/kg cohort (n = 29). The majority of patients had an ECOG performance status of 0 (5.2 mg/kg, 50.0%; 4.3 mg/kg, 58.6%), received prior bevacizumab (Avastin; 89.3%; 79.3%), received a prior PARP inhibitor (53.6%; 55.2%), and had an FRα expression of at least 75% (57.1%; 62.1%). Patients in both arms received a median of 2 prior lines of therapy (range, 1-3).

At data cutoff, 79% of patients in the 5.2-mg/kg cohort had discontinued treatment due to PD (71.4%) and adverse effects (AEs; 3.6%); 86% of patients in the 4.3-mg/kg cohort had discontinued study treatment due to PD (65.5%) and AEs (10.3%).

Safety Data

Lee explained that the safety profile of luveltamab tazevibulin was similar between the 2 doses. Additionally, rates of neutropenia were lower compared with prior studies following updated management and G-CSF prophylaxis guidelines.

In the overall population between both doses (n = 57), all patients experienced at least 1 treatment-emergent AE (TEAE), and 71.9% had grade 3 or higher TEAEs. The most common TEAEs included arthralgia (any-grade, 70.2%; grade ≥3, 12.3%), nausea (61.4%; 3.5%), constipation (54.4%; 7.0%), neutropenia (45.6%; 28.1%), fatigue (45.6%; 3.5%), myalgia (43.9%; 8.8%), abdominal pain (38.6%; 8.8%), neuropathy (38.6%; 1.8%), decreased appetite (38.6%; 0%), vomiting (35.1%; 1.8%), insomnia (29.8%; 3.5%), increased alanine aminotransferase levels (26.3%; 5.3%), and alopecia (24.6%; 0%).

Based on the phase 2 data, the optimized dose of luveltamab tazevibulin was selected as 5.2 mg/kg once every 3 weeks plus G-CSF prophylaxis for the first 2 cycles, then 4.3 mg/kg once every 3 weeks.

Reference

Lee J-Y, Oaknin A, Lorusso D, et al. Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: results from the dose-optimization stage of the REFRαME-O1 (GOG-3086, ENGOT-79OV, and APGOT-OV9) phase 2/3 study. Presented at: 2025 SGO Annual Meeting on Women’s Cancer; March 14-17, 2025; Seattle, WA. Abstract 922978.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content